Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Bay Area Cancer Care Center at Bay Area Medical Center
mi
from
Marinette, WI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Bay Area Cancer Care Center at Bay Area Medical Center
mi
from
Marinette, WI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Marshfield Clinic - Marshfield Center
mi
from
Marshfield, WI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Marshfield Clinic - Marshfield Center
mi
from
Marshfield, WI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Saint Joseph's Hospital
mi
from
Marshfield, WI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Saint Joseph's Hospital
mi
from
Marshfield, WI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Medical College of Wisconsin
mi
from
Milwaukee, WI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Medical College of Wisconsin
mi
from
Milwaukee, WI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Marshfield Clinic Minocqua Center
mi
from
Minocqua, WI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Marshfield Clinic Minocqua Center
mi
from
Minocqua, WI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Ministry Medical Group at Saint Mary's Hospital
mi
from
Rhinelander, WI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Ministry Medical Group at Saint Mary's Hospital
mi
from
Rhinelander, WI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Marshfield Clinic Rice Lake Center
mi
from
Rice Lake, WI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Marshfield Clinic Rice Lake Center
mi
from
Rice Lake, WI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Marshfield Clinic Cancer Care at Saint Michael's Hospital
mi
from
Stevens Point, WI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Marshfield Clinic Cancer Care at Saint Michael's Hospital
mi
from
Stevens Point, WI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Waukesha Memorial Hospital
mi
from
Waukesha, WI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Waukesha Memorial Hospital
mi
from
Waukesha, WI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Marshfield Clinic - Wausau Center
mi
from
Wausau, WI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Marshfield Clinic - Wausau Center
mi
from
Wausau, WI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Marshfield Clinic - Weston Center
mi
from
Weston, WI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Marshfield Clinic - Weston Center
mi
from
Weston, WI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Diagnostic and Treatment Center
mi
from
Weston, WI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Diagnostic and Treatment Center
mi
from
Weston, WI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Marshfield Clinic - Wisconsin Rapids Center
mi
from
Wisconsin Rapids, WI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Marshfield Clinic - Wisconsin Rapids Center
mi
from
Wisconsin Rapids, WI
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Rocky Mountain Oncology
mi
from
Casper, WY
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Rocky Mountain Oncology
mi
from
Casper, WY
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Welch Cancer Center
mi
from
Sheridan, WY
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Welch Cancer Center
mi
from
Sheridan, WY
Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390
An Open-label, Multi-centre Rollover Study to Assess the Safety and Efficacy of Eltrombopag in Thrombocytopenic Subjects With Hepatitis C Virus (HCV) Infection Who Are Otherwise Eligible to Initiate Antiviral Therapy (Peginterferon Alfa-2a or Peginterferon Alfa-2b Plus Ribavirin)
Status: Archived
GSK Investigational Site
mi
from
New Haven, CT
Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390
An Open-label, Multi-centre Rollover Study to Assess the Safety and Efficacy of Eltrombopag in Thrombocytopenic Subjects With Hepatitis C Virus (HCV) Infection Who Are Otherwise Eligible to Initiate Antiviral Therapy (Peginterferon Alfa-2a or Peginterferon Alfa-2b Plus Ribavirin)
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
New Haven, CT
Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390
An Open-label, Multi-centre Rollover Study to Assess the Safety and Efficacy of Eltrombopag in Thrombocytopenic Subjects With Hepatitis C Virus (HCV) Infection Who Are Otherwise Eligible to Initiate Antiviral Therapy (Peginterferon Alfa-2a or Peginterferon Alfa-2b Plus Ribavirin)
Status: Archived
GSK Investigational Site
mi
from
Honolulu, HI
Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390
An Open-label, Multi-centre Rollover Study to Assess the Safety and Efficacy of Eltrombopag in Thrombocytopenic Subjects With Hepatitis C Virus (HCV) Infection Who Are Otherwise Eligible to Initiate Antiviral Therapy (Peginterferon Alfa-2a or Peginterferon Alfa-2b Plus Ribavirin)
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Honolulu, HI
Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390
An Open-label, Multi-centre Rollover Study to Assess the Safety and Efficacy of Eltrombopag in Thrombocytopenic Subjects With Hepatitis C Virus (HCV) Infection Who Are Otherwise Eligible to Initiate Antiviral Therapy (Peginterferon Alfa-2a or Peginterferon Alfa-2b Plus Ribavirin)
Status: Archived
West Virginia University Hospitals Inc.
mi
from
Morgantown, WV
Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390
An Open-label, Multi-centre Rollover Study to Assess the Safety and Efficacy of Eltrombopag in Thrombocytopenic Subjects With Hepatitis C Virus (HCV) Infection Who Are Otherwise Eligible to Initiate Antiviral Therapy (Peginterferon Alfa-2a or Peginterferon Alfa-2b Plus Ribavirin)
Status: Archived
Updated: 1/1/1970
West Virginia University Hospitals Inc.
mi
from
Morgantown, WV
Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390
An Open-label, Multi-centre Rollover Study to Assess the Safety and Efficacy of Eltrombopag in Thrombocytopenic Subjects With Hepatitis C Virus (HCV) Infection Who Are Otherwise Eligible to Initiate Antiviral Therapy (Peginterferon Alfa-2a or Peginterferon Alfa-2b Plus Ribavirin)
Status: Archived
GSK Investigational Site
mi
from
Knoxville, TN
Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390
An Open-label, Multi-centre Rollover Study to Assess the Safety and Efficacy of Eltrombopag in Thrombocytopenic Subjects With Hepatitis C Virus (HCV) Infection Who Are Otherwise Eligible to Initiate Antiviral Therapy (Peginterferon Alfa-2a or Peginterferon Alfa-2b Plus Ribavirin)
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Knoxville, TN
Donor Stem Cell Transplant After Total-Body Irradiation in Treating Patients With Relapsed or Refractory Hematologic Cancer or Acute Myeloid Leukemia or Acute Lymphocytic Leukemia in Complete Remission
Partially HLA-Matched Irradiated Allogeneic Cellular Therapy After Reduced Intensity Total Body Irradiation
Status: Archived
University of Medicine and Dentistry - Robert Wood Johnson University Hospital
mi
from
New Brunswick, NJ
Donor Stem Cell Transplant After Total-Body Irradiation in Treating Patients With Relapsed or Refractory Hematologic Cancer or Acute Myeloid Leukemia or Acute Lymphocytic Leukemia in Complete Remission
Partially HLA-Matched Irradiated Allogeneic Cellular Therapy After Reduced Intensity Total Body Irradiation
Status: Archived
Updated: 1/1/1970
University of Medicine and Dentistry - Robert Wood Johnson University Hospital
mi
from
New Brunswick, NJ
Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant
Phase II Trial of Intravenously Administered AMD3100 (Plerixafor) for Stem Cell Mobilization in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Following a Lenalidomide Based Initial Therapy
Status: Archived
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant
Phase II Trial of Intravenously Administered AMD3100 (Plerixafor) for Stem Cell Mobilization in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Following a Lenalidomide Based Initial Therapy
Status: Archived
Updated: 1/1/1970
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant
Phase II Trial of Intravenously Administered AMD3100 (Plerixafor) for Stem Cell Mobilization in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Following a Lenalidomide Based Initial Therapy
Status: Archived
Mayo Clinic Rochester
mi
from
Rochester, MN
Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant
Phase II Trial of Intravenously Administered AMD3100 (Plerixafor) for Stem Cell Mobilization in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Following a Lenalidomide Based Initial Therapy
Status: Archived
Updated: 1/1/1970
Mayo Clinic Rochester
mi
from
Rochester, MN
Health-Related Quality of Life (QOL), Physical and Respiratory Function in Patients With Myeloma Affecting the Spine
Prospective Observation Study of Health-related QOL, Physical Function & Respiratory Function in Patients w/ Myeloma Affecting Spine: The Impact of Disease,Fractures & Effect of Vertebral Augmentation w/ Kyphoplasty
Status: Archived
University of California at San Francisco (UCSF)
mi
from
San Francisco, CA
Health-Related Quality of Life (QOL), Physical and Respiratory Function in Patients With Myeloma Affecting the Spine
Prospective Observation Study of Health-related QOL, Physical Function & Respiratory Function in Patients w/ Myeloma Affecting Spine: The Impact of Disease,Fractures & Effect of Vertebral Augmentation w/ Kyphoplasty
Status: Archived
Updated: 1/1/1970
University of California at San Francisco (UCSF)
mi
from
San Francisco, CA
IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients
A Phase 2a Study of Once Daily Intravenous Busulfan With Bortezomib, Followed by an Autologous Hematopoietic Stem Cell Transplant (HSCT) in Subjects With Relapsed Multiple Myeloma After Prior Autologous HSCT
Status: Archived
Indiana University Adult Psychiatry Clinic
mi
from
Indianapolis, IN
IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients
A Phase 2a Study of Once Daily Intravenous Busulfan With Bortezomib, Followed by an Autologous Hematopoietic Stem Cell Transplant (HSCT) in Subjects With Relapsed Multiple Myeloma After Prior Autologous HSCT
Status: Archived
Updated: 1/1/1970
Indiana University Adult Psychiatry Clinic
mi
from
Indianapolis, IN
IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients
A Phase 2a Study of Once Daily Intravenous Busulfan With Bortezomib, Followed by an Autologous Hematopoietic Stem Cell Transplant (HSCT) in Subjects With Relapsed Multiple Myeloma After Prior Autologous HSCT
Status: Archived
VA South Texas Health Care System, San Antonio
mi
from
San Antonio, TX
IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients
A Phase 2a Study of Once Daily Intravenous Busulfan With Bortezomib, Followed by an Autologous Hematopoietic Stem Cell Transplant (HSCT) in Subjects With Relapsed Multiple Myeloma After Prior Autologous HSCT
Status: Archived
Updated: 1/1/1970
VA South Texas Health Care System, San Antonio
mi
from
San Antonio, TX
IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients
A Phase 2a Study of Once Daily Intravenous Busulfan With Bortezomib, Followed by an Autologous Hematopoietic Stem Cell Transplant (HSCT) in Subjects With Relapsed Multiple Myeloma After Prior Autologous HSCT
Status: Archived
Texas Transplant Physician Group, PLLC
mi
from
San Antonio, TX
IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients
A Phase 2a Study of Once Daily Intravenous Busulfan With Bortezomib, Followed by an Autologous Hematopoietic Stem Cell Transplant (HSCT) in Subjects With Relapsed Multiple Myeloma After Prior Autologous HSCT
Status: Archived
Updated: 1/1/1970
Texas Transplant Physician Group, PLLC
mi
from
San Antonio, TX
IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients
A Phase 2a Study of Once Daily Intravenous Busulfan With Bortezomib, Followed by an Autologous Hematopoietic Stem Cell Transplant (HSCT) in Subjects With Relapsed Multiple Myeloma After Prior Autologous HSCT
Status: Archived
Huntsman Cancer Hospital
mi
from
Salt Lake City, UT
IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients
A Phase 2a Study of Once Daily Intravenous Busulfan With Bortezomib, Followed by an Autologous Hematopoietic Stem Cell Transplant (HSCT) in Subjects With Relapsed Multiple Myeloma After Prior Autologous HSCT
Status: Archived
Updated: 1/1/1970
Huntsman Cancer Hospital
mi
from
Salt Lake City, UT
Coenzyme Q10 in Older Athletes Treated With Statin Medications
A Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Efficacy of Coenzyme Q10 in Improving Mitochondrial Function in Older Athletes Treated With Statin Medications
Status: Archived
Ochsner
mi
from
New Orleans, LA
Coenzyme Q10 in Older Athletes Treated With Statin Medications
A Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Efficacy of Coenzyme Q10 in Improving Mitochondrial Function in Older Athletes Treated With Statin Medications
Status: Archived
Updated: 1/1/1970
Ochsner
mi
from
New Orleans, LA
Unrelated Donor Transplant for Malignant and Non-Malignant Disorders
Unrelated Donor Stem Cell Transplant for Patients With Malignant and Non-Malignant Disorders
Status: Archived
Columbia Presbyterian Med Ctr
mi
from
New York, NY
Unrelated Donor Transplant for Malignant and Non-Malignant Disorders
Unrelated Donor Stem Cell Transplant for Patients With Malignant and Non-Malignant Disorders
Status: Archived
Updated: 1/1/1970
Columbia Presbyterian Med Ctr
mi
from
New York, NY
X-Ray Mammography Standard of Care Protocol
X-Ray Mammography Standard of Care Protocol
Status: Archived
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
X-Ray Mammography Standard of Care Protocol
X-Ray Mammography Standard of Care Protocol
Status: Archived
Updated: 1/1/1970
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal Translocation
A Phase II, Multi-center, Non-randomized, Open-label Study of TKI258 in Patients With Relapsed or Refractory Multiple Myeloma, Who Are With or Without t(4;14) Translocation
Status: Archived
Lancanster Cancer Center
mi
from
Lancaster, PA
Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal Translocation
A Phase II, Multi-center, Non-randomized, Open-label Study of TKI258 in Patients With Relapsed or Refractory Multiple Myeloma, Who Are With or Without t(4;14) Translocation
Status: Archived
Updated: 1/1/1970
Lancanster Cancer Center
mi
from
Lancaster, PA
Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal Translocation
A Phase II, Multi-center, Non-randomized, Open-label Study of TKI258 in Patients With Relapsed or Refractory Multiple Myeloma, Who Are With or Without t(4;14) Translocation
Status: Archived
University Of Tennesse Cancer Institute
mi
from
Memphis, TN
Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal Translocation
A Phase II, Multi-center, Non-randomized, Open-label Study of TKI258 in Patients With Relapsed or Refractory Multiple Myeloma, Who Are With or Without t(4;14) Translocation
Status: Archived
Updated: 1/1/1970
University Of Tennesse Cancer Institute
mi
from
Memphis, TN
AMD 3100 for Treatment of Myelokathexis
A Phase I Study of the CXCR-4 Inhibitor AMD3100 for the Treatment of Neutropenia Due to Mutations of CXCR-4, the Myelokathexis Syndrome
Status: Archived
University of Washington Medical Center
mi
from
Seattle, WA
AMD 3100 for Treatment of Myelokathexis
A Phase I Study of the CXCR-4 Inhibitor AMD3100 for the Treatment of Neutropenia Due to Mutations of CXCR-4, the Myelokathexis Syndrome
Status: Archived
Updated: 1/1/1970
University of Washington Medical Center
mi
from
Seattle, WA
Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
Status: Archived
Huntsman Cancer Hospital
mi
from
Salt Lake City, UT
Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
Status: Archived
Updated: 1/1/1970
Huntsman Cancer Hospital
mi
from
Salt Lake City, UT
A Comparison of Ketofol (Ketamine and Propofol Admixture) Versus Propofol as Induction Agents on Hemodynamic Parameters
A Comparison of Ketofol (Ketamine and Propofol Admixture) vs. Propofol as Induction Agents on Hemodynamic Parameters
Status: Archived
Darien Pediatric Associates
mi
from
Darien, CT
A Comparison of Ketofol (Ketamine and Propofol Admixture) Versus Propofol as Induction Agents on Hemodynamic Parameters
A Comparison of Ketofol (Ketamine and Propofol Admixture) vs. Propofol as Induction Agents on Hemodynamic Parameters
Status: Archived
Updated: 1/1/1970
Darien Pediatric Associates
mi
from
Darien, CT
The Role of Maintenance Oral Clofarabine in Older Adults With Acute Myeloid Leukemia
A Phase I Feasibility Study Assessing the Role of Maintenance Oral Clofarabine in Older Adults With Acute Myeloid Leukemia
Status: Archived
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
mi
from
Chicago, IL
The Role of Maintenance Oral Clofarabine in Older Adults With Acute Myeloid Leukemia
A Phase I Feasibility Study Assessing the Role of Maintenance Oral Clofarabine in Older Adults With Acute Myeloid Leukemia
Status: Archived
Updated: 1/1/1970
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
mi
from
Chicago, IL
The Role of Maintenance Oral Clofarabine in Older Adults With Acute Myeloid Leukemia
A Phase I Feasibility Study Assessing the Role of Maintenance Oral Clofarabine in Older Adults With Acute Myeloid Leukemia
Status: Archived
Loyola University Medical Center
mi
from
Proviso, IL
The Role of Maintenance Oral Clofarabine in Older Adults With Acute Myeloid Leukemia
A Phase I Feasibility Study Assessing the Role of Maintenance Oral Clofarabine in Older Adults With Acute Myeloid Leukemia
Status: Archived
Updated: 1/1/1970
Loyola University Medical Center
mi
from
Proviso, IL
The Role of Maintenance Oral Clofarabine in Older Adults With Acute Myeloid Leukemia
A Phase I Feasibility Study Assessing the Role of Maintenance Oral Clofarabine in Older Adults With Acute Myeloid Leukemia
Status: Archived
Rush University Medical Center
mi
from
Chicago, IL
The Role of Maintenance Oral Clofarabine in Older Adults With Acute Myeloid Leukemia
A Phase I Feasibility Study Assessing the Role of Maintenance Oral Clofarabine in Older Adults With Acute Myeloid Leukemia
Status: Archived
Updated: 1/1/1970
Rush University Medical Center
mi
from
Chicago, IL
The Role of Maintenance Oral Clofarabine in Older Adults With Acute Myeloid Leukemia
A Phase I Feasibility Study Assessing the Role of Maintenance Oral Clofarabine in Older Adults With Acute Myeloid Leukemia
Status: Archived
University of Illinois College of Medicine
mi
from
Chicago, IL
The Role of Maintenance Oral Clofarabine in Older Adults With Acute Myeloid Leukemia
A Phase I Feasibility Study Assessing the Role of Maintenance Oral Clofarabine in Older Adults With Acute Myeloid Leukemia
Status: Archived
Updated: 1/1/1970
University of Illinois College of Medicine
mi
from
Chicago, IL
Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloidosis
Phase II Study of Bortezomib, Cyclophosphamide and Dexamethasone in Patients With Primary Systemic Light Chain Amyloidosis
Status: Archived
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloidosis
Phase II Study of Bortezomib, Cyclophosphamide and Dexamethasone in Patients With Primary Systemic Light Chain Amyloidosis
Status: Archived
Updated: 1/1/1970
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloidosis
Phase II Study of Bortezomib, Cyclophosphamide and Dexamethasone in Patients With Primary Systemic Light Chain Amyloidosis
Status: Archived
Mayo Clinic Rochester
mi
from
Rochester, MN
Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloidosis
Phase II Study of Bortezomib, Cyclophosphamide and Dexamethasone in Patients With Primary Systemic Light Chain Amyloidosis
Status: Archived
Updated: 1/1/1970
Mayo Clinic Rochester
mi
from
Rochester, MN
Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
A Pilot Study of Combined Plerixafor + Filgrastim for Mobilization of Peripheral Blood Stem Cells From Normal Donors
Status: Archived
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
A Pilot Study of Combined Plerixafor + Filgrastim for Mobilization of Peripheral Blood Stem Cells From Normal Donors
Status: Archived
Updated: 1/1/1970
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant
A Phase II Study of Bortezomib, Liposomal Doxorubicin, Dexamethasone, and Cyclophosphamide in Patients With Multiple Myeloma Relapsing Within 12 Months of Autologous Stem Cell Transplant
Status: Archived
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant
A Phase II Study of Bortezomib, Liposomal Doxorubicin, Dexamethasone, and Cyclophosphamide in Patients With Multiple Myeloma Relapsing Within 12 Months of Autologous Stem Cell Transplant
Status: Archived
Updated: 1/1/1970
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant
A Phase II Study of Bortezomib, Liposomal Doxorubicin, Dexamethasone, and Cyclophosphamide in Patients With Multiple Myeloma Relapsing Within 12 Months of Autologous Stem Cell Transplant
Status: Archived
Aurora Presbyterian Hospital
mi
from
Aurora, CO
Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant
A Phase II Study of Bortezomib, Liposomal Doxorubicin, Dexamethasone, and Cyclophosphamide in Patients With Multiple Myeloma Relapsing Within 12 Months of Autologous Stem Cell Transplant
Status: Archived
Updated: 1/1/1970
Aurora Presbyterian Hospital
mi
from
Aurora, CO
Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant
A Phase II Study of Bortezomib, Liposomal Doxorubicin, Dexamethasone, and Cyclophosphamide in Patients With Multiple Myeloma Relapsing Within 12 Months of Autologous Stem Cell Transplant
Status: Archived
Boulder Community Hospital
mi
from
Boulder, CO
Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant
A Phase II Study of Bortezomib, Liposomal Doxorubicin, Dexamethasone, and Cyclophosphamide in Patients With Multiple Myeloma Relapsing Within 12 Months of Autologous Stem Cell Transplant
Status: Archived
Updated: 1/1/1970
Boulder Community Hospital
mi
from
Boulder, CO
Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant
A Phase II Study of Bortezomib, Liposomal Doxorubicin, Dexamethasone, and Cyclophosphamide in Patients With Multiple Myeloma Relapsing Within 12 Months of Autologous Stem Cell Transplant
Status: Archived
Penrose Hospital
mi
from
Colorado Springs, CO
Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant
A Phase II Study of Bortezomib, Liposomal Doxorubicin, Dexamethasone, and Cyclophosphamide in Patients With Multiple Myeloma Relapsing Within 12 Months of Autologous Stem Cell Transplant
Status: Archived
Updated: 1/1/1970
Penrose Hospital
mi
from
Colorado Springs, CO
Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant
A Phase II Study of Bortezomib, Liposomal Doxorubicin, Dexamethasone, and Cyclophosphamide in Patients With Multiple Myeloma Relapsing Within 12 Months of Autologous Stem Cell Transplant
Status: Archived
Colorado Cancer Research Program CCOP
mi
from
Denver, CO
Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant
A Phase II Study of Bortezomib, Liposomal Doxorubicin, Dexamethasone, and Cyclophosphamide in Patients With Multiple Myeloma Relapsing Within 12 Months of Autologous Stem Cell Transplant
Status: Archived
Updated: 1/1/1970
Colorado Cancer Research Program CCOP
mi
from
Denver, CO
Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant
A Phase II Study of Bortezomib, Liposomal Doxorubicin, Dexamethasone, and Cyclophosphamide in Patients With Multiple Myeloma Relapsing Within 12 Months of Autologous Stem Cell Transplant
Status: Archived
Exempla Saint Joseph Hospital
mi
from
Denver, CO
Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant
A Phase II Study of Bortezomib, Liposomal Doxorubicin, Dexamethasone, and Cyclophosphamide in Patients With Multiple Myeloma Relapsing Within 12 Months of Autologous Stem Cell Transplant
Status: Archived
Updated: 1/1/1970
Exempla Saint Joseph Hospital
mi
from
Denver, CO
Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant
A Phase II Study of Bortezomib, Liposomal Doxorubicin, Dexamethasone, and Cyclophosphamide in Patients With Multiple Myeloma Relapsing Within 12 Months of Autologous Stem Cell Transplant
Status: Archived
St. Anthony Central Hospital
mi
from
Denver, CO
Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant
A Phase II Study of Bortezomib, Liposomal Doxorubicin, Dexamethasone, and Cyclophosphamide in Patients With Multiple Myeloma Relapsing Within 12 Months of Autologous Stem Cell Transplant
Status: Archived
Updated: 1/1/1970
St. Anthony Central Hospital
mi
from
Denver, CO
Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant
A Phase II Study of Bortezomib, Liposomal Doxorubicin, Dexamethasone, and Cyclophosphamide in Patients With Multiple Myeloma Relapsing Within 12 Months of Autologous Stem Cell Transplant
Status: Archived
Rose Medical Center
mi
from
Denver, CO
Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant
A Phase II Study of Bortezomib, Liposomal Doxorubicin, Dexamethasone, and Cyclophosphamide in Patients With Multiple Myeloma Relapsing Within 12 Months of Autologous Stem Cell Transplant
Status: Archived
Updated: 1/1/1970
Rose Medical Center
mi
from
Denver, CO